The University of Chicago Header Logo

Connection

Ezra Cohen to Proto-Oncogene Proteins B-raf

Back to Details
This is a "connection" page, showing publications Ezra Cohen has written about Proto-Oncogene Proteins B-raf.
Ezra Cohen
Connection Strength
0.326
Proto-Oncogene Proteins B-raf
  1. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82.
    View in: PubMed
    Score: 0.132
  2. New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6.
    View in: PubMed
    Score: 0.098
  3. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr 01; 18(7):2056-65.
    View in: PubMed
    Score: 0.096
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.